Original Research
Published on 11 Feb 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
in Cancer Endocrinology
Frontiers in Endocrinology
doi 10.3389/fendo.2020.00035
- 9,477 views
- 32 citations
